ada standards of care 2025 glp-1 dpp-4 combination not recommended 🔴 Holistic Treatment Diabetes: of ▪️ Cardiovascular risk: Use RA or SGLT2 inhibitors for glycemic control & cardiovascular risk reduction. ▪️ Heart failure: SGLT2 inhibitors Your Guide to the 2025

Clinical Pharmacology & Therapeutics, 87(6), 652662

Small amounts of whole fruits with meals Starchy vegetables such as corn, potatoes, and squash Limit or avoid carbohydrates that promote blood sugar spikes, including sweets, cakes, cookies, candy, white bread, white pasta, and sugary beverages

GLP-1RAs, particularly liraglutide, can modulate this pathway in disease-specific contexts: In neonatal hypoxic-ischemic brain injury models, liraglutide activates PI3K/Akt signaling, reducing neuronal apoptosis and improving long-term cognitive outcomes (Zeng et al., 2019

If you're on a higher-protein diet, you'll also want variety

WATCH-DM risk score predicts the prognosis of diabetic phenotype patients with heart failure and preserved ejection fraction

to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week